4/15/1993 • Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.
De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA
Clinical Neuroendocrinology Branch, National Institute of Mental Health,National Institute of Health, Bethesda, Maryland.
Biol Psychiatry 1993 Apr 15-May 1; 33 (8-9); 636-41
CSF 5-HIAA and MHPG decreased significantly… following fluoxetine treatment.
Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7687151&dopt=Abstract
De Bellis MD, Geracioti TD Jr, Altemus M, Kling MA
Clinical Neuroendocrinology Branch, National Institute of Mental Health,National Institute of Health, Bethesda, Maryland.
Biol Psychiatry 1993 Apr 15-May 1; 33 (8-9); 636-41
CSF 5-HIAA and MHPG decreased significantly… following fluoxetine treatment.
Cerebrospinal fluid (CSF) levels of the monoamine metabolites 5-hydroxyindoleacetic acid (5-HIAA), 3-methoxy-4-hydroxyphenylglycol (MHPG), and homovanillic acid (HVA) were measured in three groups: 46 healthy volunteers; 9 medication-free patients with DSM III-R major depressive disorder, recurrent; and these same 9 patients following at least 4 weeks of fluoxetine treatment at 20 mg/day. CSF monoamine metabolite levels in medication-free patients did not differ from healthy volunteers; however, CSF 5-HIAA and MHPG decreased significantly from 95.9 +/- 24.6 (all values +/- SD) to 64.2 +/- 26.1 pmol/ml and from 46.7 +/- 14.2 to 42.6 +/- 11.6 pmol/ml, respectively, following fluoxetine treatment. Fluoxetine also significantly decreased mean Hamilton Depression Rating Scale scores from 23.2 +/- 6.5 to 17.4 +/- 5.0 and significantly increased the CSF HVA/5-HIAA ratio.
PMID: 7687151, UI: 93320172
